Understanding the Impact of Immunotherapy on Head and Neck Cancer
Treatment options for patients with squamous cell cancer of the head and neck (SCCHN) have expanded with the rapid integration of immunotherapy into clinical practice. Leading expert presenters, at this a CME/CE/CPE-accredited live/on-demand head and neck cancer Satellite Symposium, included: Dr. Ezra Cohen, M.D., UC San Diego Moores Cancer Center; Robert Ferris, M.D., Ph.D., UPMC Hillman Cancer Center and Quynh-Thu Le, M.D., Stanford University Department of Radiation Oncology.
HNCA Board member Dr. Cohen presented on the rapid emergence of immunotherapy from major trials to novel combinations. He explored the science supporting the integration of immune therapy in head and neck cancer patients, including evidence on immune- or targeted-immune combinations.
These advances in treatment could not have been realized without head and neck cancer patients participating in clinical trials. HNCA encourages consideration of clinical trials and we have dedicated an entire section on our website, www.headandneck.org, to understanding clinical trials and locating head and neck clinical trials.
During the Symposium, this video of head and neck cancer survivor Bill McCone was presented. Details of Bill’s successful clinical trials immunotherapy treatment outcomes were discussed. Bill is our featured Cancer Survivor story for this October e-newsletter. You can read more of Bill’s cancer journey through his own words.
We invite you to view the head and neck cancer webcast. Through unique collaborations and advancements in care, HNCA strives to save lives.
Surviving Head and Neck Cancer Thanks to Research